Purpose: Coronavirus Disease 2019 (COVID-19) is a complex infectious pathology characterized by systemic inflammation. Monoclonal antibodies are being currently being tested to reduce inflammation, but their long-term effects are unknown. The purpose of this report is to give an insight on late manifestations of the disease, including unusual ocular involvement. Patients: We describe a case of an immunocompetent 57 years old man, presenting with a decreased visual acuity after COVID-19-related pneumonia and ARDS. He underwent mechanical ventilation and received Tocilizumab. After recovery from respiratory failure and seroconversion, SARS-CoV-2 was persistently not detected on nasopharyngeal swab, but inflammatory markers and interleukin-6 were persistently elevated. Several haemocultures confirmed Candida albicans. The ophthalmologic examination detected a unilateral (left eye) chorioretinitis. Intravenous voriconazole was administered with complete resolution of both clinical and ophthalmoscopic findings. Conclusion: This is a case report on COVID-19 respiratory distress and haematogenous candida spp. spread leading to unilateral chorioretinitis. Candidiasis is likely more common than what is reported during and after critical illness. Furthermore, anti-inflammatory targeted-therapy such as Tocilizumab, may interfere on long-term immune response. For this reason, coinfections should be carefully investigated, and ophthalmologic examination should be performed in presence of candidemia.
Select your language of interest to view the total content in your interested language